The industry might agree to savings in 2020 to bolster those negotiated in 2017, only to confront a new round of requests in 2022 or 2023. Any extension in 2020 will mean the industry just pays again for the 'certainty' it already has until mid-2022.
The price of paying twice or three times for the same 'certainty'
September 14, 2020 CommentLatest News
Latest Video
New Stories
-
Olympian joins call urging vigilance on meningococcal risk
July 15, 2025 - - Latest News -
HTA reform is fine, but why is the underpinning framework immutable?
July 15, 2025 - - Latest News -
Patient Voice Initiative announces the appointment of new president
July 15, 2025 - - Latest News -
Amplia Therapeutics announces additional confirmed partial response in ACCENT trial
July 14, 2025 - - Australian Biotech -
Imugene reports two additional complete responses in azer-cel CAR T Phase 1b trial
July 14, 2025 - - Australian Biotech -
Is Australia in a position to lecture any country about affordable access to medicines?
July 14, 2025 - - Latest News -
Biotintelect amongst groups funded to foster research commercialisation
July 13, 2025 - - Australian Biotech